摘要
目的 探讨肝细胞癌治疗前后血清β -葡萄糖醛酸酶 (β -G)活性变化规律。方法 应用酶联免疫吸附试验 (ELISA)技术测定血清 β -G活性。结果 肝癌患者血清 β -G活性滴度 (17 2± 2 4 )明显高于正常对照组 (6 5± 1 3) ,P <0 0 1;其中 12例保守治疗患者治疗前 (17 0± 2 3)与治疗后 (16 5± 1 9)无明显变化 ,P >0 0 5 ;15例栓塞介入治疗前β -G活性滴度 (17 4± 2 3)与治疗后 (10 6± 1 8)有显著差异 ,P <0 0 1;2 5例手术治疗患者 ,术后活性滴度 (9 9± 2 0 )明显低于术前 (17 1± 4 )P <0 0 1。比较手术患者β -G活性与肿瘤大小及淋巴结转移无关 ,与组织恶性程度呈正相关。结论 β -G变化对肝癌的诊断。
Objective To study the change of serum β-glucuronidase(β-G) activity before and after different therapy for hepatic carcinoma patients.Methods We detected the β-G activity in sera from 52 patients and normal controls using the ELISA technique.Results The serum β-G activity titer(17 2±2 4) in hepatic carcinoma patients was significantly higher than control group(6 5±1 3),(P<0 01);there was no significant difference before(17 0±2 3) and after(16 5±1 9) conservative therapy in 12 patients(P>0 05);there was significantly difference before(17 4±2 3) and after(10 6±1 8) embolism interventional treatment(P<0 01) in 15 cases;in 25 patients undergone operation,the β-G activity titer after operation(9 9±2 0) was significantly lower than that of before operation(17 1±2 4)(P<0 01).The β-G activity of patients was not related to the tumor size and lymph node metastasis.Conclusions β-G activity and its variation has some reference value to the diagnose,treatment and the judgement of the disease course in hepatic carcinoma patients.
出处
《中国医师杂志》
CAS
2002年第4期383-384,共2页
Journal of Chinese Physician
基金
辽宁科技攻关计划基金资助项目 (No982 2 50 0 3)
